Docket No.: 506401.0059

REMARKS/ARGUMENTS

Claims 1-19 remain pending in this application. Claim 2 has been amended so as to be

placed in independent form. Please charge \$200.00 for the additional independent claim to

Deposit Account No. 19-4409.

I. Objection to the Claim

In response to the objection to claim 2, claim 2 has been placed in independent form by

incorporating the limitations of claim 1 into claim 2. Accordingly, the objection to claim 2 as

being in improper dependent form is moot and should be withdrawn.

II. § 103 Rejection

Applicant submits that claims 1-19 are not obvious over U.S. Patent No. 5,290,775 to

Sawyer et al. (Sawyer '775) in view of U.S. Patent No. 5,720,951 to Baker (Baker), U.S. Patent

Application Publication No. 2003/0064099 to Oshlack et al. (Oshlack), U.S. Patent No.

4,005,038 to Minkoff (Minkoff), U.S. Patent No. 5,962,963 to Komer (Komer), and U.S. Patent

No. 5,281,611 to Sawyer et al. (Sawyer '611).

No Prima Facie Case of Obviousness Has Been Established

As the standard for assessing obviousness, MPEP 706.02(j) lists three requirements for

establishing a *prima facie* case of obviousness under 35 U.S.C. § 103:

(1) First, there must be some suggestion or motivation, either in the reference itself or

in the knowledge generally available to one of ordinary skill in the art, to modify the

references to arrive at the claimed invention.

(2) Second, there must be a reasonable expectation of success.

(3) Finally, the prior art references must teach or suggest all of the claim limitations.

Docket No.: 506401.0059

The teaching or suggestion to make the claimed combination and the reasonable expectation of

success must both be found in the prior art and not based on Applicant's disclosure.

It is respectfully submitted that these three requirements have not been met. Therefore,

Applicant respectfully submits that a prima facie case of obviousness for rejecting the pending

claims has not been established. Claims 1-19 are not anticipated or made obvious by Sawyer

'775 in view of Baker, Oshlack, Minkoff, Komer and Sawyer '611.

While Baker, Oshlack and Minkoff disclose the addition of a taste aversive substance to

their particular formulations, these references alone or in combination do not suggest the addition

of a taste aversive agent into a euthanasia formulation, as claimed by Applicant. See paragraphs

5-15 of the Declaration of Jack I. Shugart attached hereto as Exhibit A (hereinafter "Shugart

Declaration"). There is no suggestion or motivation from the cited references, as required for the

making of a prima facie case of obviousness, to incorporate the taste aversive substance from

Baker, Oshlack, or Minkoff into a euthanasia formulation, such as the euthanasia solution of

Sawyer '775, Komer or Sawyer '611.

More specifically, there is no suggestion or motivation from the cited references that a

taste aversive agent would be chemically compatible and chemically stable with the chemicals in

an injectable euthanasia solution. See Shugart Declaration, paragraphs 5 and 6. One of ordinary

skill in the art would have concerns that a mixture containing a euthanasia formulation and a

taste aversive agent that remained in a jar or vial for an extended period of time would separate

thus not allowing a correct dosage of an euthanasia formulation to be measured. See Shugart

Declaration, paragraph 7.

In addition, one of ordinary skill in the art would be concerned that the taste aversive

agent would interfere with the euthanasia formulation so as to diminish the effectiveness of the

Docket No.: 506401.0059

formulation and/or would interfere with the lidocaine in the euthanasia formulation so as to

deactivate it causing further pain to the animal being euthanized. See Shugart Declaration,

paragraphs 8 and 9. Even the FDA was concerned that the addition of a taste aversive agent

would cause additional pain to the animal being euthanized. See Shugart Declaration, paragraph

10.

The only cited reference that discloses or suggests using a taste aversive agent in a

pharmaceutical setting is Oshlack, which teaches adding a taste aversive agent to an opioid

analgesic. However, the chemical formulation of an opioid analgesic is quite different from the

chemical formulation of a euthanasia formulation. Just because a taste aversive agent is

chemically compatible and chemically stable with an opioid analgesic does not imply or suggest

to one of ordinary skill in the art that a taste aversive agent would be chemically compatible and

chemically stable with a euthanasia formulation. See Shugart Declaration, paragraph 13.

With no teaching or suggestion from the cited references to incorporate a taste aversive

agent into an injectable euthanasia composition, one of ordinary skill in the art would not find

such an addition obvious in view of the fact that numerous chemicals are not compatible with

euthanasia formulations. See Shugart Declaration, paragraph 14. For instance, as taught by

Sawyer '775 in column 19, lines 40-50, using isoproproyl alcohol in an euthanasia formulation

provided undesirable effects. Accordingly, there is no reasonable expectation that a person of

ordinary skill in the art relying on the cited references would think that a taste aversive agent

could be successfully incorporated into a euthanasia formulation. See Shugart Declaration,

paragraph 14.

It is important to note that the references cited for disclosing use of a taste aversive agent,

Baker, Minkoff, and Oshlack, do not disclose or suggest incorporating a taste aversive agent into

Docket No.: 506401.0059

a formulation that is intended for injection, whereas Applicant's claimed composition is an

injectable euthanasia composition. There is no disclosure or suggestion by the cited references

that a taste aversive agent would be compatible with a formula intended for injection. See

Shugart Declaration, paragraph 12. In fact, Oshlack teaches away from an injectable formulation

by teaching at paragraph 41 that "[t]he aversive agents of the present invention are preferably

used in connection with oral dosage forms...." In fact, Oshlack's only mention of injection

involves trying to prevent it.

Paragraph 21 of Oshlack, which is pointed out in the Office Action, does not change the

context of paragraph 41. Paragraph 21 merely states that a taste aversive agent is used in

Oshlack's analgesic formulation to discourage an abuser from inhaling or swallowing it.

Paragraph 21 does not even mention injection, even with respect to an abusive way to use the

formulation. Further, there is no disclosure or suggestion by the cited references of how a taste

aversive agent would affect an animal's skin and veins when injected therewith. See Shugart

Declaration, paragraph 12.

It is important to delicately balance the chemicals in the euthanasia formulation so as not

to cause a inhumane death, such as a prolonged death or unwanted side effects during the

euthanasia process. Accordingly, one of ordinary skill in the art would not assume that a taste

aversive agent could be added to a euthanasia formulation and that an effective injectable

euthanasia composition would be created. See Shugart Declaration, paragraph 15.

For the foregoing reasons, Applicant submits that claims 1-19 are not anticipated or made

obvious by Sawyer '775, in view of Baker, Oshlack, Minkoff, Komer, and Sawyer '611.

Serial No.: 10/764,222 Docket No.: 506401.0059

III. Conclusion

In view of the foregoing remarks, it is respectfully submitted that the claims are in condition for allowance and eventual issuance. Such action is respectfully requested. Should the Examiner have any further questions or comments which need be addressed in order to obtain allowance, please contact the undersigned attorney at the number listed below.

Acknowledgement of receipt is respectfully requested.

Respectfully submitted,

Susan Wharton Bell, Reg. No. 41,524

STINSON MORRISON HECKER LLP

1201 Walnut, Suite 2900

Kansas City, MO 64106-2150

Telephone: (816) 842-8600 Facsimile: (816) 691-3495